Traders should monitor upcoming clinical data readouts from the Phase 2a trial in na-SPMS and consider this a de-risking event for foralumab's mechanism in neuroinflammatory diseases. Positive human data could drive significant upside given the unmet need in Long COVID and neurodegenerative disorders.
Price Chart
Executive Summary
Tiziana Life Sciences announced positive preclinical data from a bioRxiv preprint showing intranasal foralumab reduced neuroinflammation and improved cognitive function in a mouse model of Long COVID. The study, led by prominent researchers at Yale and Harvard, supports clinical development of foralumab for post-viral neuroinflammatory conditions, including Long COVID, Alzheimer’s, and multiple sclerosis.
Key Facts
- Preclinical study demonstrated intranasal foralumab increases brain Tregs, reduces gliosis, restores neurogenesis, and rescues cognitive deficits in a Long COVID mouse model.
- Study co-led by Dr. Akiko Iwasaki (Yale) and Dr. Howard L. Weiner (Harvard), both respected in immunology and neurology.
- Human observational data show Long COVID patients have lower circulating Treg levels, supporting translational relevance.
- Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.
- Ongoing Phase 2a trial in non-active secondary progressive MS (na-SPMS); 14 patients in an expanded access program showed stability or improvement within 6 months.
Financial Impact
Non-dilutive near-term value catalyst based on preclinical validation; no direct financial impact yet.
Risk Factors
- Preprint data not yet peer-reviewed or replicated in humans.
- Clinical trials may not replicate preclinical efficacy.
- Dilution risk likely as company may need to raise capital to fund development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275177 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers